Reasons for Not Performing Mechanical Thrombectomy: A Population-Based Study of Stroke Codes.
Aged
Aged, 80 and over
Brain Ischemia
/ drug therapy
Female
Fibrinolytic Agents
/ therapeutic use
Humans
Intracranial Hemorrhages
/ drug therapy
Male
Middle Aged
Prospective Studies
Registries
/ statistics & numerical data
Stroke
/ drug therapy
Thrombectomy
/ methods
Time-to-Treatment
Tissue Plasminogen Activator
/ therapeutic use
intracranial hemorrhages
ischemic stroke
neuroimaging
therapeutics
thrombectomy
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
pubmed:
23
7
2021
medline:
6
1
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Mechanical thrombectomy (MT) is effective for acute ischemic stroke (AIS) in selected patients with large intracranial vessel occlusion. A minority of patients with AIS receive MT. We aimed to describe the reasons for excluding patients with AIS for MT. We evaluated patients with AIS in a prospective population-based multicenter registry (Codi Ictus Catalunya registry) that includes all stroke code activations from January to June 2018 in Catalonia, Spain. We analyzed the major reasons for not treating with MT. Stroke code was activated in 3060 patients. Excluding 355 intracranial hemorrhages and 502 stroke mimics, resulted in 2203 patients with AIS (mean age 72.8±13.8 years; 44.6% were women). Of the patients with AIS, 405 (18.4%) were treated with MT. We analyzed the reasons for not treating with MT. The following reasons were considered not modifiable: absence of large intracranial vessel occlusion (922, 41.9%), transient ischemic attack (206, 9.4%), and more than one cause (124, 5.6%). The potentially modifiable reasons for not performing MT by changing selection criteria were as follows: an intracranial artery occlusion that was considered inaccessible or not indicated (48, 2.2%); clinical presentation that was considered too mild to be treated (222, 10.1%); neuroimaging criteria (129, 5.9%), age/prior modified Rankin Scale score/medical comorbidities (129, 5.9%), and therapeutic time window >8 hours (16, 0.7%). In our area, considering all potentially modifiable causes for not performing MT, the percentage of patients with AIS eligible for MT could increase from 18.4% to a maximum of 43.1%. The clinical benefit of this increase is still uncertain and should be confirmed in future trials. Criteria for stroke code activation must be considered for the generalizability of these results.
Sections du résumé
Background and Purpose
Mechanical thrombectomy (MT) is effective for acute ischemic stroke (AIS) in selected patients with large intracranial vessel occlusion. A minority of patients with AIS receive MT. We aimed to describe the reasons for excluding patients with AIS for MT.
Methods
We evaluated patients with AIS in a prospective population-based multicenter registry (Codi Ictus Catalunya registry) that includes all stroke code activations from January to June 2018 in Catalonia, Spain. We analyzed the major reasons for not treating with MT.
Results
Stroke code was activated in 3060 patients. Excluding 355 intracranial hemorrhages and 502 stroke mimics, resulted in 2203 patients with AIS (mean age 72.8±13.8 years; 44.6% were women). Of the patients with AIS, 405 (18.4%) were treated with MT. We analyzed the reasons for not treating with MT. The following reasons were considered not modifiable: absence of large intracranial vessel occlusion (922, 41.9%), transient ischemic attack (206, 9.4%), and more than one cause (124, 5.6%). The potentially modifiable reasons for not performing MT by changing selection criteria were as follows: an intracranial artery occlusion that was considered inaccessible or not indicated (48, 2.2%); clinical presentation that was considered too mild to be treated (222, 10.1%); neuroimaging criteria (129, 5.9%), age/prior modified Rankin Scale score/medical comorbidities (129, 5.9%), and therapeutic time window >8 hours (16, 0.7%).
Conclusions
In our area, considering all potentially modifiable causes for not performing MT, the percentage of patients with AIS eligible for MT could increase from 18.4% to a maximum of 43.1%. The clinical benefit of this increase is still uncertain and should be confirmed in future trials. Criteria for stroke code activation must be considered for the generalizability of these results.
Identifiants
pubmed: 34289711
doi: 10.1161/STROKEAHA.120.032648
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2746-2753Investigateurs
Rebeca Marín
(R)
Francisco Purroy
(F)
Joaquín Serena
(J)
David Canovas
(D)
Manuel Gómez-Choco
(M)
Xavier Ustrell
(X)
Josep Zaragoza
(J)
Jerzy Krupinski
(J)
Natalia Mas Sala
(N)
Ernest Palomeras
(E)
Dolors Cocho
(D)
Josep Maria Aragonés
(J)
Núria López
(N)
Eduard Sanjurjo
(E)
Dolors Carrión Duch
(D)
Mercè López
(M)
M Cruz Almendros Rivas
(MC)
Jordi Monedero Boado
(J)
Esther Catena
(E)
Esther Catena
(E)
Maria Rybyeba
(M)
Gloria Diaz
(G)
Commentaires et corrections
Type : CommentIn